Patient Outcomes

在开发新技术的过程中，必须考虑到患者对技术创新可接受性的看法。由于患者参与自己的护理，因此满足其需求的医疗设备可以产生更好的治疗效果。在这个项目中，我们采取全球性的方法来开发和评估检测宫颈癌的技术，考虑影响宫颈筛查和诊断的各个层面的因素：从分子到患者及其社区。在项目4中，我们将考虑新兴技术对发达国家和发展中国家患者结局的影响。 和发展中国家。在发达国家，巴氏涂片和活检后诊断和治疗轨迹的多次延迟可能会降低依从性，并增加接受不利结果的女性的心理困扰。在发展中国家和发达国家服务不足的地区，标准护理程序需要的资源是不可用的。此外，关于宫颈癌筛查的文化信仰往往存在，这对广泛的筛查计划构成障碍。在这个项目中，我们正在开发技术，以解决发达国家和发展中国家当前技术的局限性。在这笔赠款的支持下，正在开发的新兴技术旨在通过以下方式改善筛查结果：（1）在更短的时间内提高准确性，这可以支持单次就诊的诊断和治疗;（2）更多的自动化，促进非专家提供者更广泛地使用该技术;（3）侵入性更小的测试，从而增加患者的舒适度和减少痛苦。为了实现项目4的目标，我们对项目3中提出的两项临床试验中的805名参与者进行了患者态度、痛苦、焦虑、疼痛和优先事项的调查，该试验将在温哥华和休斯顿的六个临床中心进行。我们还将评估阿巴拉契亚、得克萨斯-墨西哥边境和尼日利亚伊巴丹的卫生保健提供的具体障碍。

The patient's perspective on the acceptability of technological innovation must be taken into account during the development of new technologies. Because patients are involved in their own care, medical devices that address their needs can produce better treatment outcomes. In this program project, we take a global approach to developing and assessing technologies to detect cervical cancer, considering factors at all levels that affect cervical screening and diagnosis: from the molecular to the patients and their communities. In Project 4, we will consider the effects of emerging technologies on patient outcomes in both developed and developing worlds. In developed countries, the multiple delays in the diagnosis and treatment trajectory after Papanicolaou smear and biopsy can reduce adherence and increase psychological distress for women receiving unfavorable results. In developing countries and underserved areas of the developed world, standard-of-care procedures require resources that are not available. In addition, cultural beliefs about screening for cervical cancer often exist that pose barriers to widespread screening programs. In this program project, we are developing technologies to address limitations in current technologies for both developed and developing countries. Emerging technologies under development with support from this grant aim to improve screening outcomes through (1) improved accuracy in less time, which can support diagnosis and treatment in a single visit; (2) more automation, facilitating wider use of the technology by non-expert providers; and (3) less invasive testing, which results in increased comfort and less distress for patients. To achieve the goals of Project 4, we take surveys of patient attitudes, distress, anxiety, pain, and priorities from 805 participants in the two clinical trials proposed in Project 3, which will be conducted at six clinical sites in Vancouver and Houston. We will also assess specific barriers to health care delivery in Appalachia, the Texas-Mexico border, and in Ibadan, Nigeria.